BET inhibitors in cancer therapeutics: A patent review

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 4, 2016, Pages 505-522

  Ghoshal, Anirban ^a   Yugandhar, D ^a,b   Srivastava, Ajay Kumar ^a,b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

anti cancer; BET; Bromodomain; Bromodomain and Extra Terminal Proteins

Indexed keywords

BROMODOMAIN INHIBITOR; ISOXAZOLE DERIVATIVE; PYRAZOLOPYRIDINE DERIVATIVE; PYRIDOPYRAZINE DERIVATIVE; PYRROLOPYRIDINE DERIVATIVE; PYRROLOPYRROLONE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NUCLEAR PROTEIN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NEOPLASM; PATENT; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPUTER SIMULATION; DRUG DEVELOPMENT; MOLECULAR MODEL; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PATENTS AS TOPIC;

EID: 84961198877     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1159299     Document Type: Review

References (83)

1. [cited 2015 Dec 29]. Available from: http://www.who.int/cancer/en/.
2. Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst. 2002;94(2):78-79.
3. Vidler LR, Brown N, Knapp S, et al. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem. 2012;55(17):7346-7359.
4. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337-356.
5. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med. 2011;13:e29.
6. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214-231.
7. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529-533.
8. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146 (6):904-917.
9. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478 (7370):524-528.
10. Banerjee C, Archin N, Michaels D, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012;92(6):1147-1154.
11. Zhu J, Gaiha GD, John SP, et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep. 2012;2(4):807-816.
12. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468 (7327):1119-1123.
13. Denis GV. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med. 2010;10(55):489-499.
14. Anand P, Brown JD, Lin CY, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154 (3):569-582.
15. Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014;74:98-102.
16. Sun Y, Huang J, Song K. BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Exp Ther Med. 2015;10(6):2319-2324.
17. Matzuk MM, McKeown MR, Filippakopoulos P, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150 (4):673-684.
18. Bisgrove DA, Mahmoudi T, Henklein P, et al.. Conserved P-TEFbinteracting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci USA. 2007;104(34):13690-13695.
19. Jang MK, Mochizuki K, Zhou M, et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19 (4):523-534.
20. Yang Z, Yik JH, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535-545.
21. Gehling VS, Hewitt MC, Vaswani RG, et al. Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Med Chem Lett. 2013;4(9):835-840.
22. Xue X, Zhang Y, Liu Z, et al.. Discovery of benzo[cd]indol-2 (1H)-ones as potent and specific BET bromodomain inhibitors: structure-based virtual screening, optimization, and biological evaluation. J Med Chem. 2015;in press. doi:10.1021/acs.jmedchem. 5b01511.
23. Raux B, Voitovich Y, Derviaux C, et al.. Exploring selective inhibition of the first bromodomain of the human bromodomain and extraterminal domain (BET) proteins. J Med Chem. 2015;in press. doi:10.1021/acs.jmedchem.5b01708.
24. Ran X, Zhao Y, Liu L, et al. Structure-based design of γ-carboline analogues as potent and specific BET bromodomain inhibitors. J Med Chem. 2015;58(12):4927-4939.
25. Baud MGJ, Lin-Shiao E, Zengerle M, et al.. New synthetic routes to triazolo-benzodiazepine analogues: expanding the scope of the bump-and-hole approach for selective bromo and extra-terminal (BET) bromodomain inhibition. J Med Chem. 2015;in press. doi:10.1021/acs.jmedchem.5b01135.
26. Zhang G, Smith SG, Zhou M-M. Discovery of chemical inhibitors of human bromodomains. Chem Rev. 2015;115(21):11625-11668.
27. Smith SG, Zhou M-M. The bromodomain: a new target in emerging epigenetic medicine. ACS Chem Biol. 2015; in press. doi:10.1021/acschembio.5b00831.
28. Smith SG, Sanchez R, Zhou M-M. Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem Biol. 2014;21(5):573-583.
29. French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63 (2):304-307.
30. French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27(15):2237-2242.
31. Filippakopoulos P, Qi J, Picaud S, et al.. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
32. Glaxo Smith Kline. A study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other cancers. Bethesda (MD): U. S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01587703).
33. Glaxo Smith Kline. A dose escalation study to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01943851).
34. Wyspianska B, Bannister A, Barbieri I, et al. BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. Leukemia. 2014;28(1):88-97.
35. Oncoethix GmbH. A phase I, dose-finding study of the bromodomain (Brd) inhibitor OTX015/ MK-8628 in hematologic malignancies (MK-8628-001). Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01713582).
36. Oncoethix GmbH. A dose-finding study of OTX105/MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628- 003). Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT02259114).
37. Bonetti P, Ponzoni M, Tibiletti MG, et al. The BRD-inhibitor OTX015 shows pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2012;48(6):163.
38. Tensha Therapeutics. A dose escalation and cohort expansion study of TEN-010 in patients with acute myeloid leukemia and myelodysplastic syndrome. Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT02308761).
39. Tensha Therapeutics. A two part, multicenter, open-label study of TEN-010 given subcutaneously. Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT01987362).
40. Constellation Pharmaceuticals. A phase 1 study evaluating CPI- 0610 in patients with progressive lymphoma. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT01949883).
41. Constellation Pharmaceuticals. A phase 1 study evaluating CPI- 0610 in patients with previously treated multiple myeloma. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT02157636).
42. Constellation Pharmaceuticals. A phase 1 study evaluating CPI- 0610 in patients with acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms, and myelofibrosis. Bethesda (MD): U.S. National Institutes of Health; 2016. (ClinicalTrials.gov, NCT02158858).
43. Lejeune P, Sugawara T, Gelato KA, et al. BAY 1238097, a novel BET inhibitor with strong efficacy in haematological tumor models. In: proceedings of the 106th annual meeting of the American Association for Cancer Research, Philadelphia, PA April 18-22, 2015. Cancer Res. 2015;75(15):3524.
44. Garnier J-M, Sharp PS, Burns CJ. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat. 2014;24(2):185-199.
45. Mitsubishi Tanabe Pharma Corporation. Antitumor agent. WO2009084693. 2009.
46. Bayer Pharma AG. 6-substituted 2,3-benzodiazepines. WO2015121226. 2015.
47. Bayer Pharma AG. 6,9-disubstituted 1-phenyl-3H-2,3-benzodiazepines and their use as bromodomain inhibitors. WO2015121227. 2015.
48. Bayer Pharma AG. 9-substituted 2,3-benzodiazepines. WO2015121230. 2015.
49. Bayer Pharma AG. 1-phenyl-3H-2,3-benzodiazepines and their use as bromodomain inhibitors. WO2015121268. 2015.
50. Kainos Medicine, Inc. Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer. WO2015156601. 2015.
51. Oncoethix SA. A BET-BRD inhibitor represents a novel agent for Alk positive anaplastic large cell lymphoma. WO2015018520. 2015.
52. Oncoethix SA. BET bromodomain inhibitor shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL). WO2015018522. 2015.
53. Oncoethix SA. A novel BET-BRD inhibitor for treatment of solid tumors. WO2015018523. 2015.
54. Oncoethix GmbH. A study assessing tOTX015 in combination with Azacitidine (AZA) or AZA single agent in patients with newlydiagnosed acute myeloid leukemia (AML) not candidate for Standard Intensive Induction Therapy (SIIT). Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT02303782).
55. Oncoethix GmbH. A trial with dose optimization of OTX015 in recurrent glioblastoma multiforme (GBM) patients (OTX015-107). Bethesda (MD): U.S. National Institutes of Health; 2015. (ClinicalTrials.gov, NCT02296476).
56. Kyorin Pharmaceutical Co., Ltd. Heterocyclic compounds. WO2015129927. 2015.
57. Novartis AG. Pyrrolopyrrolone derivatives and their use as BET inhibitors. WO2015075665. 2015.
58. Incyte Corporation. Bicyclic heterocycles as BET protein inhibitors. WO2015081189. 2015.
59. Incyte Corporation. Bicyclic heterocycles as BET protein inhibitors. WO2015081203. 2015.
60. Incyte Corporation. Tricyclic heterocycles as BET protein inhibitors. WO2015095492. 2015.
61. Incyte Corporation. 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[ 3,4c]pyridin-7(6H)-ones as inhibitors of BET proteins. WO2015164480. 2015.
62. Bayer Pharma AG. Modified BET-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones. WO2015004075. 2015.
63. Bayer Pharma AG. Substituted dihydropyrido[3,4-B]pyrazinones as dual inhibitors of BET proteins and polo-like kinases. WO2015011084. 2015.
64. Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors. WO2015002754. 2015.
65. Chung C, Coste H, White JH, et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011;54(11):3827-3838.
66. Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors. WO2015004533. 2015.
67. Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors. WO2015004534. 2015.
68. Aurigene Discovery Technologies Limited. Bicyclic heterocyclic derivatives as bromodomain inhibitors. WO2015104653. 2015.
69. The Regents of the University of Michigan. 9H-pyrimido[4,5-B] indoles and related analogs as bromodomain inhibitors. WO2015131005. 2015.
70. Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors. WO2015074064. 2015.
71. Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors. WO2015015318. 2015.
72. SignalRx Pharmaceuticals, Inc. Novel heterocyclic compound classes for signalling modulation. US20150315207. 2015.
73. Icahn School of Medicine at Mount Sinai. Cyclic vinylogous amides as bromodomain inhibitors. WO2015031824. 2015.
74. Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors. WO2015074081. 2015.
75. Medivation Technologies, Inc. Aromatic compounds, compositions and uses thereof. WO2015184405. 2015.
76. University of Dundee. Enzymes functional probes. WO2015079259. 2015.
77. Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders. WO2011143669. 2011.
78. Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using Bromodomain and Extra-Terminal (BET) protein inhibitors. WO2015070020. 2015.
79. Infinity Pharmaceuticals, Inc. Combination therapies. WO2015160986. 2015.
80. The Brigham and Women's Hospital, Inc.; President and Fellows of Harvard College. The NSD3 inhibitors for treatment of cancers. WO2015112809. 2015.
81. Palacky University, Olomouc. Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimen for overcoming resistance. WO2015144102. 2015.
82. INSERM (Institut National De La Santé Et De La Recherche Medicale), Institut Jean Paoli and Irene Calmettes, Université D'Aix Marseille, Centre National De La Recherche Scientifique (CNRS). Methods for the treatment of T-cell acute lymphoblastic leukemias. WO2015144636. 2015.
83. Constellation Pharmaceuticals, Inc. Expression levels of BCL-xL, BCL2, BCL-w, and BAD and cancer therapies. WO2015153871. 2015